rheumatology
Medicines

Biologics not associated with worse COVID-19 outcomes in RA, PsA or AS patients

Use of biologics by patients with immune-related inflammatory disease and SARS-CoV-2 infection does not appear to be associated with worse COVID-19 outcomes. In Correspondence to the editor of the NEJM, a prospective cases series comprised 86 patients with underlying rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, inflammatory bowel disease, or related conditions and confirmed or ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic